Vasarya Therapeutics, Inc.

Funding and NIH signals

• NIH award NIH awarded $1.13M (SBIR Phase II 5R44HL170936-03, continuation, notice Sep 4, 2026). NIH RePORTER 5R44HL170936-03 (Sep 4, 2026)
  Evidence (1 event)

  • Sep 4, 2026 · NIH RePORTER 5R44HL170936-03
    Organization: VASARYA THERAPEUTICS, INC.; City/State: CAMDEN, DE; Project number: 5R44HL170936-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-09-04; FY total cost (award amount): 1126840; Administering IC: National Heart Lung and Blood Institute; Project title: Translating a Novel Therapeutic Approach to the Treatment for Idiopathic Pulmonary Fibrosis; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals